000009755 001__ 9755
000009755 005__ 20240124114330.0
000009755 0247_ $$2DOI$$a10.6083/nz806044h
000009755 037__ $$aETD
000009755 245__ $$aRole of platelet tyrosine kinases in atherosclerosis
000009755 260__ $$bOregon Health and Science University
000009755 269__ $$a2022
000009755 336__ $$aDissertation
000009755 502__ $$bPh.D.
000009755 520__ $$aAtherosclerosis is the leading cause of cardiovascular disease, accounting for nearly 30% of deaths in the United States. Patients with late-stage atherosclerosis suffer from life-threatening complications, such as myocardial infarctions, ischemic strokes, aneurysms, and multi-organ failure. Many current treatment options, including anti-platelet and anti-coagulant therapies, although moderately effective at alleviating or preventing thrombotic events of atherosclerosis, carry a risk for bleeding and hemorrhagic complications. Thus, there remains a need to further understand the molecular basis of hemostasis and thrombosis in order develop safer and more effective therapies. The goal of this thesis is to investigate mechanisms in which tyrosine kinase inhibitors reduce thrombotic events, while maintaining hemostasis processes in atherosclerosis, to guide therapeutic interventions for future patients.
000009755 542__ $$fIn copyright - single owner
000009755 650__ $$aBlood Platelets$$015667
000009755 650__ $$aAtherosclerosis$$036329
000009755 650__ $$aProtein-Tyrosine Kinases$$024762
000009755 6531_ $$aoxldl
000009755 6531_ $$aibrutinib
000009755 691__ $$aSchool of Medicine$$041369
000009755 692__ $$aDepartment of Biomedical Engineering$$041397
000009755 7001_ $$aZheng, Tony J.
000009755 8564_ $$9e22170d1-cc9d-42fa-9214-9c6dae8b058e$$s5278395$$uhttps://digitalcollections.ohsu.edu/record/9755/files/Zheng.Tony.2022.pdf
000009755 905__ $$a/rest/prod/nz/80/60/44/nz806044h
000009755 909CO $$ooai:digitalcollections.ohsu.edu:9755$$pstudent-work
000009755 980__ $$aTheses and Dissertations